Načítá se...
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
With rates of obesity and diabetes rising across the world, effective therapies to treat hyperglycemia and its associated comorbidities continue to be in demand. Empagliflozin is a highly selective sodium glucose transporter-2 inhibitor that improves serum glucose levels by inducing glucosuria. Take...
Uloženo v:
| Vydáno v: | Clin Pharmacol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4847607/ https://ncbi.nlm.nih.gov/pubmed/27186083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S77754 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|